Posts

Showing posts with the label ANDA

API & IP Brief: FDA CGT Approvals Review, Sodium Thiosulfate Patent Ruling & Biopharma Updates

Image
API & IP Intelligence Brief: FDA Competitive Generic Therapy (CGT) Review & Purity Patent Rulings Target Keywords: Competitive Generic Therapy, CGT exclusivity, FDA ANDA approvals, Zydus Lifesciences, Amneal lanreotide, Hope Medical v Accord, sodium thiosulfate patent, API purity specifications, Paragraph IV litigation, Teva R&D Day . Six-Month FDA Competitive Generic Therapy (CGT) Review (Apr – Oct 2026) Between April 28 and October 19, 2026, the FDA approved 45 Abbreviated New Drug Applications (ANDAs) holding Competitive Generic Therapy (CGT) designations, up from 41 in the prior six-month period . However, only 12 approvals (27%) qualified for 180-day CGT market exclusivity, continuing a downward eligibility trend from 71% in 2019 to 26% so far in 2026 . Under Section 506H of the FD&C Act, CGT incentivises entry into off-patent or sole-source drugs facing inadequate generic competition . To unlock 180-day exclusivity, the first approved applicant must have ha...

FDA Q3 2026 DMF Filings, Delhi HC Patent Ruling & Biocon BPCIA Settlement

Image
Summary: 5-minute read The latest intelligence update covers US FDA Drug Master File (DMF) trends for Q3 2026, landmark pharmaceutical IP jurisprudence from the Delhi High Court, and key regulatory and biosimilar litigation settlements . 1. US FDA Q3 2026 Type II DMF Filings Landscape A total of 316 Type II (Drug Substance) DMFs were submitted in Q3 2026, with India and China accounting for over 85% of total volume : Geographic Distribution: China led with 148 filings (47%), prioritising peptide therapeutics (Semaglutide, Tirzepatide, Orforglipron), exosomes, and bioprocessing media . India followed with 123 submissions (39%), focusing on small-molecule oncology kinase inhibitors, cardiometabolic therapies, and complex anti-infectives . The US and Rest of World accounted for 5% (17) and 9% (28), respectively . Top Filing Entities: Suyog Life Sciences topped the rankings with 11 filings (primarily key starting materials and advanced intermediates), followed by Apitoria Pharma...